MEDLIVE (02192) has announced its interim results for the fiscal year 2026, with revenue reaching approximately RMB 315 million, marking a 1% year-on-year increase. Profit attributable to owners of the parent company stood at around RMB 162 million, reflecting a 4% growth compared to the same period last year.

The company's adjusted net profit reached approximately RMB 171 million, representing a 2.4% year-on-year increase. Basic earnings per share amounted to RMB 21.87 cents.

According to the announcement, the revenue growth was primarily driven by an increase in income from precision marketing and corporate solutions.